Is JAZZ Stock Undervalued?

A comprehensive valuation analysis of Jazz Pharmaceuticals Plc (JAZZ) examining current multiples, intrinsic value, and comparing to analyst expectations.

Updated April 19, 2026•8 min read•View Full Analysis

Valuation Verdict

↑

Potentially Undervalued

3395200754.8% upside potential

Based on our analysis, Jazz Pharmaceuticals Plc appears to be potentially undervalued at the current price of $203.42. Our fair value estimate of $6906517578.87 suggests upside potential of approximately 3395200754.8%.

Current Valuation Metrics

Valuation ratios help us understand how the market is pricing JAZZ relative to its fundamentals. Let's examine the key multiples investors are paying today.

P/E Ratio

N/A

P/B Ratio

2.82

Moderate

P/S Ratio

2.93

Moderate

EV/EBITDA

57.54

High

Understanding the Metrics

P/E Ratio: Not currently profitable or data unavailable.
P/B Ratio: A P/B of 2.82 means investors pay $2.82 for every $1 of book value.
P/S Ratio: The price-to-sales ratio of 2.93 indicates how much investors value each dollar of revenue.
EV/EBITDA: This ratio of 57.54 helps compare JAZZ to peers while accounting for debt.

Fair Value Estimate

Using a discounted cash flow (DCF) model, we estimate the intrinsic value of Jazz Pharmaceuticals Plc stock. This fundamental analysis looks at the company's ability to generate future cash flows and discounts them back to today's value.

Current Price

$203.42

Fair Value Estimate

$6906517578.87

Implied Return+3395200754.8%

Our DCF model suggests JAZZ may be undervalued by approximately 3395200754.8%. This implies the market may be pricing in more pessimistic growth expectations than our base case scenario.

Analyst Price Targets

Wall Street analysts provide price targets based on their fundamental research and models. Let's see how the consensus view compares to the current price.

Current Price

$203.42

→

Analyst Target

$223.71

Implied Upside10.0%

The consensus analyst price target of $223.71 suggests 10.0% upside potential from current levels. Analysts appear optimistic about the stock's prospects.

Investment Conclusion

Bottom Line

Based on our comprehensive valuation analysis, Jazz Pharmaceuticals Plc (JAZZ) appears to be undervalued at $203.42. With a fair value estimate of $6906517578.87, the stock offers potential upside for long-term investors willing to wait for the market to recognize its intrinsic value.

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.